142PD - The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer

Date 14 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Targeting EGFR and ALK driven tumours
Topics Cytotoxic agents
Bioethics, Legal, and Economic Issues
Non-small-cell lung cancer
Therapy
Biological therapy
Presenter Jie Zhang
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors J. Zhang1, Y. Song2, Z. Zhou3, C. Zhang2, J. Signorovitch2
  • 1Global Oncology, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 2Health Economics And Outcomes Research, Analysis Group, Inc., 02199 - Boston/US
  • 3Health Economics And Outcomes Research, Analysis Group, Inc., 10020 - New York/US

Abstract

Background

Ceritinib has demonstrated rapid and durable antitumor activity in ALK+ non-small cell lung cancer (NSCLC). This study projected the work productivity gain and its associated societal impact of ceritinib as compared to chemotherapy for patients with crizotinib-experienced ALK+ NSCLC in the EU5 countries. 142PDT1 Table: Per-patient and total societal impacts on productivity of ceritinib vs. chemotherapy for the EU5 countries over 5 years

 UKFranceGermanyItalySpain
Productivity gain per patient (working day)7067686565
Societal cost saving per patient (2014 euro)€ 12,420€ 18,641€ 17,150€ 14,656€ 11,058
Total societal productivity gain (working day)33,52831,98940,73429,42220,495
Total societal saving (2014 euro)€ 5,981,367€ 8,854,670€ 10,232,265€ 6,661,244€ 3,492,396

Methods

An economic model was built to estimate the probabilities of ALK+ NSCLC patients being at stable, progressive disease, or death state in each monthly cycle based on efficacy inputs from clinical trials for ceritinib and from literature for chemotherapy. Labor costs and probabilities of restoring work productivity, based on inputs from public databases or publications, were incorporated to calculate work productivity for patients and their informal caregivers, and compared between patients initiating ceritinib vs. chemotherapy over a 5-year time horizon. Model parameters were varied in one-way sensitivity analyses.

Results

Compared to chemotherapy, ceritinib treatment was associated with 65 (Italy) to 70 (UK) additional working days per patient (including associated caregiver) over 5 years. Societal cost savings per patient due to work productivity gain ranged from €11,058 (Spain) to €18,641 (France). Across countries, 54–61% of these gains occurred for treated patients, while the remainder occurred for their informal caregivers. At the country level, the societal savings from ceritinib ranged from €3.5 to 10.2 million. The results were robust under sensitivity analyses.

Conclusions

Ceritinib treatment for crizotinib-experienced ALK+ NSCLC was associated with greater work productivity for patients and their informal caregivers compared to treatment with chemotherapy. These savings represent an economic benefit of ceritinib treatment from the societal perspective, which would occur in addition to clinical and quality-of-life benefits and impacts on medical expenditures.

Clinical trial identification

Legal entity responsible for the study

Novartis Pharmaceuticals Corporation

Funding

Novartis Pharmaceuticals Corporation

Disclosure

J. Zhang: Employee of Novartis and company stock ownership. Y. Song, Z.-Y. Zhou, C. Zhang, J. Signorovitch: Employee of Analysis Group, a consulting firm that received funding from Novartis to conduct this study.